GDFATHER trial: what clinicians have said so far
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
- NCT04725474 ↗
- Active, not recruiting
- CatalYm GmbH
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on GDFATHER (visugromab plus nivolumab; visugromab in advanced-stage, relapsed/refractory solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GDFATHER so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built | |
| 1 post on Bluesky, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- visugromab (CTL-002); nivolumab
- Arms
- Phase 1 (Part A; dose escalation): CTL-002 Monotherapy + Checkpoint Inhibitor Combination · Experimental
- Phase 2 (Part B; expansion): visugromab (CTL-002) + Checkpoint Inhibitor Combination · Experimental
- Enrollment
- 199
- Primary outcomes
- Adverse Events (Parts A & B)
- Determination of DLT and MTD (Part A)
- Evaluation of clinical efficacy according RECIST V1.1 (Part B)
- Sponsor
- CatalYm GmbH
- Start
- Dec 9, 2020
- Primary completion
- Apr 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04725474 · updated Aug 19, 2026
Publications
linked from the registry- Melero I, de Miguel M, Cabanas EG, de Velasco G, Joerger M, Martin-Liberal J, Reig M, Konig D, Trojan J, Goebeler ME, Schuler M, Alonso G, Dummer R, Rodriguez-Ruiz ME, Yarza R, Pretelli G, Esteban-Villarubia J, Koster KL, Viltro PS, Sanduzzi-Zamparelli M, Laubli H, Koch C, Sayehli C, Gromke T, Racca F, Ramelyte E, Galle PR, Necchi A, Reck M, Trajanoski Z, Hackl H, Gogolla F, Billing J, Sattmann T, Wischhusen J, Schuberth-Wagner C, Akdemir J, Lichtenegger FS, Auckenthaler A, Fox M, Klar K, Fettes P, Liebig M, Amin A, Sachdeva S, Hermann F, Leo E. Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors. J Hematol Oncol. 2026 Jul 9. doi: 10.1186/s13045-026-01818-2. Online ahead of print. PubMed 42426863